Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2014. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), and Connected Persons, in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions.
Transaction Details:
- Date of Purchase: October 2, 2014
- Price per Share: 1,415.94 pence
- Transaction Type: Reinvestment of dividends paid on Ordinary Shares held in the GlaxoSmithKline ShareReward Plan.
Material Changes
The filing reports changes in share interests for the following individuals resulting from the dividend reinvestment plan:
- Directors/PDMR: Sir Andrew Witty (36 shares), Mr S Dingemans (10 shares), Mr R G Connor (44 shares), Mr S A Hussain (9 shares), Mr D S Redfern (52 shares), Ms C Thomas (52 shares), Mr P C Thomson (24 shares), Dr P J T Vallance (29 shares), Ms E Walmsley (5 shares), and Mrs V A Whyte (34 shares).
- Connected Persons: Mrs K Thomson (14 shares, connected to Mr P C Thomson).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider share purchases.
Investor Verification Checklist
- Verify the total number of shares purchased by each Director and PDMR listed in the notification.
- Confirm the share price of 1,415.94 pence per Ordinary Share on October 2, 2014.
- Ensure the transactions were executed solely through the GlaxoSmithKline ShareReward Plan dividend reinvestment mechanism.